Biocept Expands Commercial Offering of CNSideâ„¢ Assay to Most Cancers that Metastasize to the Central Nervous System
Copyright 2022, Business Wire.
news
2022-10-17 12:00:00

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patients with metastatic melanoma. Previously validated for lung, breast, and all other carcinomas, Biocept's CNSide is a proprietary CSF assay designed to better detect and inform treatment decisions for patients with metastatic cancers involving the central nervous system (CNS). The new CNSide for mela
